Hepatitis B Infection (Acute)
Overview
Plain-Language Overview
Acute Hepatitis B Infection is a viral illness that affects the liver, an organ essential for filtering blood and processing nutrients. It is caused by the Hepatitis B virus (HBV), which spreads through contact with infected blood or bodily fluids. This infection can cause symptoms like fatigue, jaundice (yellowing of the skin and eyes), and abdominal pain. The liver inflammation from the virus can temporarily impair its ability to function properly. Most people recover fully, but some may develop more serious liver problems. The infection primarily impacts the immune system's response to the virus in the liver.
Clinical Definition
Acute Hepatitis B Infection is defined as a recent infection with the Hepatitis B virus (HBV) leading to inflammation of the liver. The core pathology involves viral replication within hepatocytes, triggering an immune-mediated hepatocellular injury. Transmission occurs mainly through percutaneous or mucosal exposure to infectious blood or body fluids. Clinically, it presents with symptoms such as jaundice, elevated liver enzymes, and systemic signs like fever and malaise. The infection is significant due to its potential to cause acute liver failure or progress to chronic hepatitis, increasing the risk of cirrhosis and hepatocellular carcinoma. The presence of HBsAg and IgM anti-HBc antibodies are key markers of acute infection.
Inciting Event
Exposure to HBV-contaminated blood or body fluids through sexual contact or needle sharing.
Perinatal transmission during childbirth from an infected mother to the neonate.
Accidental needle-stick injury or mucosal exposure in healthcare settings.
Use of unsterilized medical or dental equipment in endemic regions.
Latency Period
The incubation period ranges from 6 weeks to 6 months, typically around 90 days.
Symptoms usually develop 2 to 3 months after exposure to HBV.
Viral replication and antigen expression begin during the asymptomatic incubation phase.
Diagnostic Delay
Initial symptoms are often nonspecific and resemble other viral illnesses, leading to misdiagnosis.
Lack of awareness or suspicion in patients without classic risk factors delays testing.
Mild or subclinical cases may not prompt early serologic testing for HBV.
Overlap with other causes of hepatitis can obscure diagnosis without specific HBV serologies.
Clinical Presentation
Signs & Symptoms
Fatigue and malaise as common early symptoms
Anorexia and nausea often accompany acute hepatitis
Dark urine due to increased conjugated bilirubin excretion
Clay-colored stools from decreased bile secretion
Right upper quadrant abdominal pain from liver inflammation
Low-grade fever during the prodromal phase
History of Present Illness
Patients typically present with prodromal symptoms including fatigue, malaise, anorexia, and low-grade fever.
Development of right upper quadrant abdominal pain and jaundice follows the prodrome.
Dark urine and pale stools occur due to cholestasis from hepatocellular injury.
Symptoms peak over several days to weeks and then gradually resolve in most cases.
Some patients may develop fulminant hepatic failure with encephalopathy and coagulopathy.
Past Medical History
History of previous HBV infection or vaccination affects susceptibility and presentation.
Prior immunosuppression or chronic liver disease can worsen clinical course.
Use of hepatotoxic drugs or alcohol may exacerbate liver injury.
History of other sexually transmitted infections or intravenous drug use increases risk.
Family History
Family members may have chronic HBV infection due to vertical or horizontal transmission.
No direct genetic inheritance, but familial clustering occurs in endemic areas.
Family history of chronic liver disease or hepatocellular carcinoma may be relevant.
Physical Exam Findings
Jaundice with yellowing of the sclera and skin due to elevated bilirubin
Hepatomegaly with a tender, enlarged liver on palpation
Right upper quadrant tenderness indicating liver inflammation
Scleral icterus as a classic sign of hyperbilirubinemia
Mild fever may be present during the acute phase
Diagnostic Workup
Diagnostic Criteria
Diagnosis of acute hepatitis B infection is established by detecting hepatitis B surface antigen (HBsAg) and IgM antibody to hepatitis B core antigen (IgM anti-HBc) in serum. Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels indicate hepatocellular injury. The absence of hepatitis B surface antibody (anti-HBs) confirms lack of immunity. Serologic testing differentiates acute from chronic infection by the presence of IgM anti-HBc, which is typically positive only in acute or recent infection. Liver function tests and clinical presentation support the diagnosis.
Pathophysiology
Key Mechanisms
Hepatitis B virus (HBV) infects hepatocytes, leading to viral replication and expression of viral antigens.
The host's immune response, particularly cytotoxic CD8+ T cells, causes hepatocyte injury and inflammation.
Immune-mediated hepatocellular necrosis results in elevated liver enzymes and clinical hepatitis.
Formation of immune complexes can contribute to extrahepatic manifestations such as polyarteritis nodosa.
Acute infection may trigger fulminant hepatitis due to massive immune-mediated liver damage.
| Involvement | Details |
|---|---|
| Organs | Liver is the primary organ involved in hepatitis B infection, responsible for viral replication and clinical manifestations. |
Immune system organs such as lymph nodes and spleen are involved in mounting the immune response against the virus. | |
| Tissues | Liver parenchyma is the main tissue affected by hepatitis B infection, showing inflammation and hepatocyte necrosis. |
| Cells | Hepatocytes are the primary target cells infected by hepatitis B virus, leading to liver inflammation and injury. |
Cytotoxic CD8+ T cells mediate immune clearance of infected hepatocytes, contributing to liver damage. | |
Kupffer cells act as liver-resident macrophages that participate in the inflammatory response during infection. | |
| Chemical Mediators | Interferon-gamma is produced by activated T cells and promotes antiviral activity against hepatitis B virus. |
Tumor necrosis factor-alpha (TNF-α) contributes to hepatocyte apoptosis and inflammation in acute hepatitis B. | |
Alanine aminotransferase (ALT) is a key enzyme marker elevated in serum indicating hepatocellular injury. |
Treatments
Pharmacological Treatments
Entecavir
- Mechanism:
Inhibits hepatitis B virus DNA polymerase, blocking viral replication.
- Side effects:
Headache
Fatigue
Nausea
- Clinical role:
First-line
Tenofovir
- Mechanism:
Nucleotide analog that inhibits hepatitis B virus reverse transcriptase.
- Side effects:
Renal toxicity
Bone mineral density loss
Nausea
- Clinical role:
First-line
Non-pharmacological Treatments
Supportive care including hydration and rest to manage symptoms of acute hepatitis B infection.
Avoidance of alcohol and hepatotoxic drugs to prevent further liver injury.
Regular monitoring of liver function tests and viral load to assess disease progression.
Prevention
Pharmacological Prevention
Recombinant hepatitis B vaccine administered in a 3-dose series
Hepatitis B immune globulin (HBIG) for post-exposure prophylaxis
Antiviral therapy (e.g., tenofovir) in high-risk chronic carriers to reduce transmission
Non-pharmacological Prevention
Safe sex practices including condom use to prevent sexual transmission
Screening of blood products to prevent transfusion-related infection
Avoidance of sharing needles among intravenous drug users
Universal precautions in healthcare settings to reduce occupational exposure
Prenatal screening and management to prevent vertical transmission
Outcome & Complications
Complications
Fulminant hepatic failure with rapid liver decompensation
Cholestatic hepatitis causing prolonged jaundice
Acute liver failure requiring urgent transplantation
Reactivation of chronic hepatitis B in immunosuppressed patients
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Hepatitis B Infection (Acute) versus Hepatitis A Infection
Hepatitis B Infection (Acute) | Hepatitis A Infection |
|---|---|
Parenteral, sexual, or perinatal transmission with blood or body fluids | Fecal-oral transmission, often from contaminated food or water |
Positive HBsAg and anti-HBc IgM antibodies | Positive anti-HAV IgM antibodies |
Potential progression to chronic infection and carrier state | Typically self-limited with no chronic infection |
Hepatitis B Infection (Acute) versus Hepatitis C Infection
Hepatitis B Infection (Acute) | Hepatitis C Infection |
|---|---|
Bloodborne and sexual transmission, including perinatal | Primarily bloodborne transmission, often via IV drug use |
Positive HBsAg and anti-HBc IgM antibodies | Positive anti-HCV antibodies and HCV RNA PCR |
Often acute symptomatic phase with possible chronicity | High rate of chronic infection with insidious onset |
Hepatitis B Infection (Acute) versus Autoimmune Hepatitis
Hepatitis B Infection (Acute) | Autoimmune Hepatitis |
|---|---|
Presence of viral antigens and antibodies specific to hepatitis B | Presence of autoantibodies such as ANA, anti-smooth muscle antibodies |
Elevated transaminases with positive HBsAg and anti-HBc IgM | Elevated IgG levels with negative viral serologies |
Managed primarily with antiviral agents | Improves with immunosuppressive therapy |
Hepatitis B Infection (Acute) versus Acute Hepatitis E Infection
Hepatitis B Infection (Acute) | Acute Hepatitis E Infection |
|---|---|
Bloodborne and sexual transmission, including perinatal | Fecal-oral transmission, often in developing countries with poor sanitation |
Positive HBsAg and anti-HBc IgM antibodies | Positive anti-HEV IgM antibodies |
Potential for chronic infection and carrier state | Usually self-limited but severe in pregnant women |
Hepatitis B Infection (Acute) versus Drug-Induced Hepatitis
Hepatitis B Infection (Acute) | Drug-Induced Hepatitis |
|---|---|
No recent hepatotoxic drug exposure, presence of viral markers | Recent use of hepatotoxic drugs such as acetaminophen or isoniazid |
Elevated transaminases with positive HBsAg and anti-HBc IgM | Elevated transaminases without viral serologies |
Requires antiviral treatment and may progress to chronicity | Improves with withdrawal of offending drug |